Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DelveInsight | PRODUCT CODE: 1129041

Cover Image

PUBLISHER: DelveInsight | PRODUCT CODE: 1129041

Thrombocytopenia - Epidemiology Forecast - 2032

PUBLISHED:
PAGES: 112 Pages
DELIVERY TIME: 1-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF (Site License)
USD 7900
PDF (Global License)
USD 11850

Add to Cart

DelveInsight's 'Thrombocytopenia Overview - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Thrombocytopenia historical and forecasted epidemiology as well as the Thrombocytopenia epidemiology trends in the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Thrombocytopenia Understanding

Thrombocytopenia Overview

Thrombocytopenia Understanding

Thrombocytopenia Overview

Thrombocytopenia is a condition in which the blood has an abnormal number of blood cell fragments called platelets. Platelets are made in the bone marrow along with other kinds of blood cells. They travel through the blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets are also called thrombocytes because a clot is also called a thrombus. When a patient's blood has few platelets, mild-to-serious bleeding can occur inside the body (internal bleeding), underneath the skin, or from the skin's surface.

Continued in the report…

Causes of Thrombocytopenia

  • Thrombocytopenia has many etiologies, such as bone marrow failure, bone marrow suppression (e.g., from medication, chemotherapy, or irradiation), chronic alcohol abuse, myelodysplastic syndrome, autoimmune syndromes, etc.

Thrombocytopenia Indications

  • Immune thrombocytopenic purpura (ITP): An acquired immune-mediated disorder characterized by isolated thrombocytopenia and the absence of other conditions or agents known to induce thrombocytopenia. The incidence is 100 cases per 1 million persons annually, and approximately 50% of cases occur in children. Immune thrombocytopenic purpura in children often resolves spontaneously but is more insidious and chronic in adults. The risk of bleeding correlates to the severity of thrombocytopenia. Patients may present without symptoms, minimal bleeding, or serious hemorrhage (e.g., mucosal, intracranial, gastrointestinal, genitourinary). Older patients, patients on antiplatelet therapy, and patients with comorbid conditions may have severe bleeding manifestations.
  • Drug-induced thrombocytopenia: One of the most common types of thrombocytopenia in the outpatient setting is drug-induced thrombocytopenia. An epidemiologic study from Europe and the US showed an annual incidence of 10 cases/1 million persons, but numbers could be higher in older and hospitalized patients. Drug-induced thrombocytopenia is suspected in all patients presenting with an acute drop in platelet count. Most patients with drug-induced thrombocytopenia have moderate-to-severe thrombocytopenia reaching a nadir platelet count of 20 × 103/μL. During treatment, physicians should ask specific questions about the use of any medications, including nutritional supplements and over-the-counter remedies being taken by the patient. Quinine is a common cause of drug-induced thrombocytopenia and is often missed in the patient's history.

Continued in the report…..

Thrombocytopenia Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Thrombocytopenic Purpura (TTP), Total Cases of Immune Thrombocytopenia (ITP), Total Cases of Thrombocytopenia in Chronic Liver Disease, Total Cases of Chemotherapy-induced Thrombocytopenia, Total Number of Cases of Heparin-induced Thrombocytopenia, and Total Cases of Thrombocytopenia scenario in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Thrombocytopenia Detailed Epidemiology Segmentation

Key Findings

  • In 2021, the total cases of Thrombocytopenia in the 7MM countries were 2,608,095, and these cases are anticipated to increase during the study period. The US accounted for 1,045,247 cases of Thrombocytopenia in 2021.
  • Among the European countries, Germany had the highest number of cases of Thrombocytopenia in 2021, i.e., 453,441 cases, followed by the UK which had 269,422 cases in 2021. On the other hand, Italy had the lowest number of cases of Thrombocytopenia, i.e. 127,166 cases in 2021.
  • The highest cases of TTP were seen in US which accounted for 6,002 cases in 2021.
  • Japan, in 2021, accounted for 58,261 cases of Chemotherapy-induced Thrombocytopenia, which is expected to increase during the study period.
  • The maximum number of cases of Heparin-induced Thrombocytopenia in 2021 were recorded in Germany out of all the EU-5 countries and Spain accounted for the least number of cases.

Scope of the Report:

  • The report covers a descriptive overview of Thrombocytopenia, explaining its procedure, types, indications, and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the Thrombocytopenia risk and burden.
  • The report provides the segmentation of the epidemiology for 7MM by segmented by 'Total Cases of Thrombocytopenic Purpura (TTP), Total Cases of Immune Thrombocytopenia (ITP), Total Cases of Thrombocytopenia in Chronic Liver Disease, Total Cases of Chemotherapy-induced Thrombocytopenia, Total Number of Cases of Heparin-induced Thrombocytopenia, and Total Cases of Thrombocytopenia'.

Report Highlights:

  • 11-Year Forecast of Thrombocytopenia
  • 7MM Coverage
  • Total Cases of Thrombocytopenia Molecular Alteration- Type-specific Cases of Thrombocytopenia
  • Total Cases of Thrombocytopenia by Indication

Key Questions Answered

  • What are the risk, burdens, and unmet needs of Thrombocytopenia?
  • What is the historical Thrombocytopenia patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Thrombocytopenia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Thrombocytopenia?
  • Out of the countries mentioned above, which country would have the highest cases of Thrombocytopenia during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to buy:

The Thrombocytopenia report will allow the user to -

  • Develop business strategies by understanding the trends, shaping and driving the 7MM Thrombocytopenia epidemiology.
  • The Thrombocytopenia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Thrombocytopenia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Geographies Covered

  • The United States
  • The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Product Code: DIEI0229

Table of Contents

1. Key Insights

2. Report Introduction

3. Thrombocytopenia Overview At A Glance

4. Thrombocytopenia: Future Prospects

5. Executive Summary Of Thrombocytopenia

6. Key Events

7. Disease Background And Overview

  • 7.1. Introduction
  • 7.2. Causes Of Thrombocytopenia
    • 7.2.1. Emergent Thrombocytopenia
    • 7.2.2. Non-emergent Thrombocytopenia
  • 7.3. Symptoms Of Thrombocytopenia
  • 7.4. Diagnosis Of Thrombocytopenia
    • 7.4.1. Chemotherapy-induced Thrombocytopenia
    • 7.4.2. Immune Thrombocytopenia (ITP)
    • 7.4.3. Heparin-induced Thrombocytopenia (HIT)
    • 7.4.4. Thrombocytopenia Associated With Chronic Liver Disease
    • 7.4.5. TTP
  • 7.5. Diagnosis Of Thrombocytopenia
    • 7.5.1. Clinical Practice Guideline On The Evaluation And Management Of ITP
    • 7.5.2. International Society On Thrombosis And Hemostasis Guidelines For The Diagnosis Of TTP
    • 7.5.3. Guidelines On The Diagnosis Of HIT: Second Edition

8. Treatment Of Thrombocytopenia

  • 8.1. Etiology-specific Treatment
    • 8.1.1. Inherited Thrombocytopenia
    • 8.1.2. Immune Thrombocytopenia (ITP)
    • 8.1.3. Thrombotic Thrombocytopenic Purpura
    • 8.1.4. Drug-induced Thrombocytopenia/DITP And Heparin-induced Thrombocytopenia
    • 8.1.5. Thrombocytopenia In Pregnancy
  • 8.2. Treatment Guidelines Of Thrombocytopenia
    • 8.2.1. Guidelines On The Diagnosis And Management Of Heparin-induced Thrombocytopenia: Second Edition
  • 8.3. American Society Of Hematology (Ash) 2019 Guidelines For Immune Thrombocytopenia
    • 8.3.1. Management Of Adult Patients With Newly Diagnosed ITP
    • 8.3.2. Management Of Adults With ITP Who Are Corticosteroid-dependent Or Do Not Have A Response To Corticosteroids

9. Methodology

10. Epidemiology And Patient Population

  • 10.1. Key Findings
  • 10.2. Assumptions And Rationale
  • 10.3. The United States
  • 10.4. The EU5
    • 10.4.1. Japan
  • 10.5. Epidemiology Scenario: 7MM
    • 10.5.1. Total Cases of Thrombocytopenia in the 7MM
  • 10.6. The United States
    • 10.6.1. Total Cases of Thrombocytopenic Purpura (TTP) in the United States
    • 10.6.2. Total Cases of Immune Thrombocytopenia (ITP) in the United States
    • 10.6.3. Total Cases of Thrombocytopenia in Chronic Liver Disease in the United States
    • 10.6.4. Total Cases of Chemotherapy-induced Thrombocytopenia in the United States
    • 10.6.5. Total Number of Cases of Heparin-induced Thrombocytopenia in the United States
    • 10.6.6. Total Cases of Thrombocytopenia in the United States
  • 10.7. EU-5 Epidemiology
    • 10.7.1. Total Cases of Thrombocytopenic Purpura (TTP) in the EU-5
    • 10.7.2. Total Cases of Immune Thrombocytopenia (ITP) in the EU-5
    • 10.7.3. Total Cases of Thrombocytopenia in Chronic Liver Disease in the EU-5
    • 10.7.4. Total Cases of Chemotherapy-induced Thrombocytopenia in the EU-5
    • 10.7.5. Total Number of Cases of Heparin-induced Thrombocytopenia in the EU-5
    • 10.7.6. Total Cases of Thrombocytopenia in the EU-5
  • 10.8. Japan Epidemiology
    • 10.8.1. Total Cases of Thrombocytopenic Purpura (TTP) in Japan
    • 10.8.2. Total Cases of Immune Thrombocytopenia (ITP) by Indications in Japan
    • 10.8.3. Total Cases of Thrombocytopenia in Chronic Liver Disease in Japan
    • 10.8.4. Total Cases of Chemotherapy-induced Thrombocytopenia in Japan
    • 10.8.5. Total Number of Cases of Heparin-induced Thrombocytopenia in Japan
    • 10.8.6. Total Cases of Thrombocytopenia in Japan

11. Appendix

  • 11.1. Report Methodology
  • 11.2. Bibliography

12. Delveinsight Capabilities

13. Disclaimer

14. About Delveinsight

Product Code: DIEI0229

List of Tables

  • Table 1: Summary of Thrombocytopenia, Epidemiology (2019-2032)
  • Table 2: Key Events
  • Table 3: Differential Diagnosis of Thrombocytopenia According to the Clinical Scenario
  • Table 4: Total Cases of Thrombocytopenia in the 7MM (2019-2032)
  • Table 5: Total Cases of Thrombocytopenic Purpura (TTP) in the United States (2019-2032)
  • Table 6: Total Cases of Immune Thrombocytopenia (ITP) in the United States (2019-2032)
  • Table 7: Total Cases of Thrombocytopenia in Chronic Liver in the United States (2019-2032)
  • Table 8: Total Cases of Chemotherapy-induced Thrombocytopenia in the United States (2019-2032)
  • Table 9: Total Number of Cases of Heparin-induced Thrombocytopenia in the United States (2019-2032)
  • Table 10: Total Cases of Thrombocytopenia in the United States (2019-2032)
  • Table 11: Total Cases of Thrombocytopenic Purpura (TTP) in the EU-5 (2019-2032)
  • Table 12: Total Cases of Immune Thrombocytopenia (ITP) by Indications in the EU-5 (2019-2032)
  • Table 13: Total Cases of Thrombocytopenia in Chronic Liver Disease in the EU-5 (2019-2032)
  • Table 14: Total Cases of Chemotherapy-induced Thrombocytopenia in the EU-5 (2019-2032)
  • Table 15: Total Number of Cases of Heparin-induced Thrombocytopenia in the EU-5 (2019-2032)
  • Table 16: Total Cases of Thrombocytopenia in the EU-5 (2019-2032)
  • Table 17: Total Cases of Thrombocytopenic Purpura (TTP) in Japan (2019-2032)
  • Table 18: Total Cases of Immune Thrombocytopenia (ITP) in Japan (2019-2032)
  • Table 19: Total Cases of Thrombocytopenia in Chronic Liver Disease in Japan (2019-2032)
  • Table 20: Total Cases of Chemotherapy-induced Thrombocytopenia in Japan (2019-2032)
  • Table 21: Total Number of Cases of Heparin-induced Thrombocytopenia in Japan (2019-2032)
  • Table 22: Total Cases of Thrombocytopenia in Japan (2019-2032)

List of Figures

  • Figure 1: Etiology of Thrombocytopenia
  • Figure 2: Cellular Pathogenic Mechanisms in ITP
  • Figure 3: Thrombocytopenia: Diagnostic Algorithm Starting With the Complete Blood Count (CBC)
  • Figure 4: Diagnostic Algorithm to Confirm or Rule out HIT in Patients Who Have not Undergone Bypass Surgery
  • Figure 5: General Approach and Mechanism to the Diagnosis of Thrombocytopenia in Liver Disease
  • Figure 6: Flow Chart for ADAMTS13 Laboratory Investigation in TTP
  • Figure 7: Algorithm for the management of thrombocytopenia
  • Figure 8: Total Cases of Thrombocytopenia in the 7MM (2019-2032)
  • Figure 9: Total Cases of Thrombocytopenic Purpura (TTP) in the United States (2019-2032)
  • Figure 10: Total Cases of Immune Thrombocytopenia (ITP) in the United States (2019-2032)
  • Figure 11: Total Cases of Thrombocytopenia in Chronic Liver Disease in the United States (2019-2032)
  • Figure 12: Total Cases of Chemotherapy-induced Thrombocytopenia in the United States (2019-2032)
  • Figure 13: Total Number of Cases of Heparin-induced Thrombocytopenia in the United States (2019-2032)
  • Figure 14: Total Cases of Thrombocytopenia in the United States (2019-2032)
  • Figure 15: Total Cases of Thrombocytopenic Purpura (TTP) in the EU-5 (2019-2032)
  • Figure 16: Total Cases of Immune Thrombocytopenia (ITP) in the EU-5 (2019-2032)
  • Figure 17: Total Cases of Thrombocytopenia in Chronic Liver Disease in the EU-5 (2019-2032)
  • Figure 18: Total Cases of Chemotherapy-induced Thrombocytopenia in the EU-5 (2019-2032)
  • Figure 19: Total Number of Cases of Heparin-induced Thrombocytopenia in the EU-5 (2019-2032)
  • Figure 20: Total Cases of Thrombocytopenia in the EU-5 (2019-2032)
  • Figure 21: Total Cases of Thrombocytopenic Purpura (TTP) in Japan (2019-2032)
  • Figure 22: Total Cases of Immune Thrombocytopenia (ITP) in Japan (2019-2032)
  • Figure 23: Total Cases of Thrombocytopenia in Chronic Liver Disease in Japan (2019-2032)
  • Figure 24: Total Cases of Chemotherapy-induced Thrombocytopenia in Japan (2019-2032)
  • Figure 25: Total Number of Cases of Heparin-induced Thrombocytopenia in Japan (2019-2032)
  • Figure 26: Total Cases of Thrombocytopenia in Japan (2019-2032)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!